20
Dec
biosyn Arzneimittel GmbH appoints Pascal Voltzenlugel as Managing Director/CEO – Guarantee for a positive development
biosyn Arzneimittel GmbH announces Pascal Voltzenlugel as Managing Director/CEO - ensuring positive development.
Fellbach, November 1st 2023 - At the shareholders' meeting of biosyn Arzneimittel GmbH, Pascal Voltzenlugel was appointed as the new Managing Director and CEO of the company. This key decision marks a significant milestone for biosyn and is...
20
Dec
Recruitment of a pharmaceutical leader found to guarantee the positive development of biosyn Arzneimittel GmbH
The shareholders' meeting of biosyn appointed Pascal Voltzenlugel as Managing Director/CEO of biosyn Arzneimittel GmbH. The Managing Director represents the company exclusively.
Pascal Voltzenlugel is a pharmacist, a graduate of the University of Strasbourg and holds an MBA (Master of Business Administration) from Noema Business Scholl. He has outstanding knowledge in...
20
Sep
WOCOIO 2023 – WORLD CONGRESS OF INTEGRATIVE ONCOLOGY
WOCOIO - WORLD CONGRESS OF INTEGRATIVE ONCOLOGY
WOCOIO offers the most recent therapeutic developments in Integrative Oncology and networking with the world’s top physicians in this field!
biosyn Arzneimittel GmbHÂ invites you to attend the first version of WOCOIO!
For registration, please click here:Â World Congress Of Integrative Oncology
Organized by ESIO: www.esio.info
More info: www.wocoio.com
25
Jun
Stifterverband honors work of biosyn
Since 2014, the Stifterverband has recognized research-based companies for the special responsibility they assume for the state and society with the "Innovative through Research" seal. biosyn Arzneimittel GmbH has been awarded the seal for the years 2020 and 2021.
Thomas Stiefel, biosyn co-founder and managing director, is pleased about this. "The...
29
Apr
Against forgetting – What biosyn does in the fight against Alzheimer’s disease
In Germany, around 1.7 million people have Alzheimer's disease or another dementia disorder. This is a term used to describe various conditions in which mental performance declines quite sharply over time. By far the majority of those affected have Alzheimer's. More than 300,000 new cases occur every year.
There is no...
23
Mar
biosyn with approvals in 27 countries
biosyn Arzneimittel GmbH (selenase, calcivitase, zincotase), a company specializing in trace elements, is active in many parts of the world. Currently, there are approvals for the company's products in 27 countries.
The company specifically focuses on internationalization. Opportunities in new markets are regularly reviewed. biosyn is a leader in selenium products....
25
Feb
New product innovations from biosyn
biosyn Arzneimittel GmbH is launching two new dietary supplements in Germany - myflora comfort and myfemella. Both products contain sporebiotics and botanicals.
Most classic bacterial cultures, such as lactobacilli or bifidobacteria, do not survive the acidic environment of the stomach. To make them more resistant, they are often chemically coated. Nevertheless,...
19
Feb
Selenium products from biosyn to France
biosyn Arzneimittel GmbH is a leader in high-dose selenium injections. Now the medium-sized family-owned company has received approval for France for a selenase injection preparation.
Managing partner Thomas Stiefel is particularly pleased about this positive decision. "We have convinced the French authorities of the quality of our products." He points out...
18
Feb
biosyn now represented with selenase in Georgia
biosyn Arzneimittel GmbH is a leader in selenium products. Now the medium-sized family-owned company is represented in Georgia with selenase. Another step in the internationalization strategy of the hidden champion.
Managing partner Ortwin Kottwitz emphasizes the importance of foreign markets. "We regularly examine opportunities in new markets and are pleased when...
15
Feb
Sales setup in the United Kingdom Kora Healthcare and biosyn launch sales collaboration
Dublin, Ireland, 21 January 2022. biosyn Arzneimittel GmbH and Kora Healthcare have entered into an exclusive licensing agreement for the marketing and distribution of selenase®, a medicinal product for the treatment of proven selenium deficiency, in the United Kingdom.
As the marketing authorization holder, biosyn Arzneimittel GmbH had been working with...
14
Jan
biosyn now also offers selenium products in the USA
Dietary supplements represent health, beauty and vitality into old age. A large proportion of Americans regularly take one or more dietary supplements to promote their own health. Starting in the spring of 2021, biosyn Arzneimittel GmbH will begin selling a selection of selenium products in the USA through its new...
15
Sep
Update storage advice – MEPTID no longer needs to be refrigerated
Update storage advice – MEPTID no longer needs to be refrigerated
There is good news about MEPTID, the WHO stage II opioid for moderate to severe pain. MEPTID can now be stored at room temperature as a rule.
This changes the storage advice "Do not store above 30 °C" regarding special precautions...
12
Oct
biosyn & AXON Neuroscience intensify cooperation and plan a joint venture
biosyn Arzneimittel GmbH and Axon Neuroscience have long enjoyed a trusting cooperation in the development of Axon's therapeutic vaccine AADVac1 against Alzheimer's disease.
The family-owned company based in Fellbach near Stuttgart is an important partner of the Czech biotechnology company. Axon Neuroscience relies on the carrier immunocyanine (modified KLH) produced by...
15
Sep
Against a fading mind – KLH carrier for Alzheimer’s vaccine
Against a fading mind - KLH carrier for Alzheimer's vaccine
The body lives and the mind wanes. In patients with Alzheimer's disease, mental performance declines quite sharply over time. So far, there is no drug or therapy that can cure the disease. Medications can at best delay or somewhat alleviate the...
